NCT02465060 2026-04-13
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
11 trialsNCT02115048 2019-12-26
Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone
Translational Research in Oncology
Phase 2 Terminated
NCT01271725 2019-06-17
LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures
Boehringer Ingelheim
Phase 2 Completed
NCT02511847 2016-04-15
Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib
National Taiwan University Hospital
Phase 2 Unknown
NCT01441596 2015-09-07
Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases
Boehringer Ingelheim
Phase 2 Completed
NCT00431067 2014-06-09
Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy
Boehringer Ingelheim
Phase 2 Completed
NCT01594177 2014-03-13
DAFNE
GBG Forschungs GmbH
Phase 2 Completed
NCT00425854 2013-12-31
An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-negative Metastatic Breast Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT00826267 2013-12-31
6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab
Boehringer Ingelheim
Phase 2 Completed
NCT00708214 2013-12-30
BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT01531764 2013-10-18
BIBW 2992 (Afatinib) and Vinorelbine
University of Magdeburg
Phase 2 Terminated